OMALIZUMAB ASTMA BOSHQARUVIDA: KO'RSATMALARDAN AMALIYOTGA
DOI:
https://doi.org/10.69891/Kalit so‘zlar:
og'ir astma allergik astma anti-IgE omalizumab biologik terapiya zo'rayishlar ko'rsatmalarni amalga oshirishAbstrak
Og'ir astma kattalarda yuqori yuklamali holat bo'lib qolmoqda, bu esa ingalyatsiya qilingan davolashni optimallashtirish, rioya qilish, komorbidlikni nazorat qilish va qo'zg'atuvchi omillarni yumshatishdan so'ng fenotipga yo'naltirilgan qo'shimcha terapiyani talab qiladigan heterojen endotiplar tufayli yuzaga keladi. Immunoglobulin E (IgE) ni nishonga oluvchi insonlashtirilgan monoklonal antikor bo'lgan Omalizumab og'ir allergik (IgE vositachiligidagi) astma bilan og'rigan kattalar uchun biologik variant bo'lib, asosiy xalqaro strategiyalar va jamiyat ko'rsatmalariga ko'ra standart yuqori dozali ingalyatsiya qilingan kortikosteroid/uzoq muddatli ẞ2-agonistga asoslangan rejimlar nazoratga erisha olmagan hollarda qo'shimcha terapiya sifatida belgilanadi. Mexanik jihatdan, omalizumab aylanib yuruvchi erkin IgE bilan bog'lanadi va asosiy effektor hujayralardagi yuqori affinlikli IgE retseptorlarini pasaytirish orqali IgE-FcɛRI signalizatsiyasini kamaytiradi, shu bilan allergen tomonidan boshqariladigan mast hujayralar, bazofil faollashuvi va 2-toifa yallig'lanishni susaytiradi. Tasodifiy sinovlar va real hayotdagi tadqiqotlardan olingan dalillar, noyob anafilaksi va marketingdan keyingi yurak-qon tomir xavfi kabi xavfsizlik signallariga doimiy e'tibor qaratgan holda, tanlangan bemorlarda alevlenmelerning klinik jihatdan sezilarli darajada kamayishi, simptomlarni nazorat qilish va hayot sifatining yaxshilanishi va steroidlarni tejashning afzalliklarini qo'llab-quvvatlaydi. Ushbu sharhda ko'rsatmalar bo'yicha tavsiyalar, bemorni tanlash, dozalash va monitoring qilish tamoyillari hamda kattalar amaliyotiga moslashtirilgan amaliy amalga oshirish bosqichlari umumlashtirilib, muntazam parvarishda javobni baholash va davolashni optimallashtirishga urg'u beriladi.References
1. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention: 2025 Update. 2025.
2. Global Initiative for Asthma (GINA). Difficult-to-treat & severe asthma in adolescent and adult patients: Diagnosis and Management (Guide). 2024.
3. Holguin F, Cardet JC, Chung KF, et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2020;55(1).
4. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–373.
5. Humbert M, Busse W, Hanania NA, et al. Omalizumab in asthma: an update on recent developments. J Allergy Clin Immunol Pract. 2014.
6. Solèr M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J. 2001.
7. Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001.
8. Hanania NA, Alpan O, Hamilos DL, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med. 2011.
9. Hanania NA, Wenzel S, Rosén K, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013.
10. Bousquet J, Humbert M, Gibson PG, et al. Real-world effectiveness of omalizumab in severe allergic asthma: a meta-analysis of observational studies. J Allergy Clin Immunol Pract. 2021.
11. Humbert M, Taillé C, Mala L, et al. Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study. Eur Respir J. 2018.
12. Siergiejko Z, Świebocka E, Smith N, et al. Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients. Curr Med Res Opin. 2011.